The new generation GnRH antagonists have introduced a new era in ovulation induction. The international medical community tends to recognize GnRH antagonists's protocols as first-line treatment in assisted reproduction, as they offer many advantages such as:The new generation GnRH antagonists have introduced a new era in ovulation induction. The international medical community tends to recognize GnRH antagonists's protocols as first-line treatment in assisted reproduction, as they offer many advantages such as:

• They are friendly to the patient because they have shorter duration, fewer days of injections, lower doses, lower costs and fewer complications.
• They are offered for personalized ivf treatment, according to the ovarian response of each woman.
• They are associated with significantly lower chance of complications (like OHSS) compared to the long protocol, but offer similar pregnancy rates in women with PCOS.Read more in our published study (Lainas et al., 2010 Hum Reprod).
• They offer significantly higher pregnancy rates in poor responders compared to the short protocol.Read more in our published study (Lainas et al., 2008 Hum Reprod)
• They are associated with higher pregnancy rates when the antagonist is initiated earlier than the traditional 6th day of stimulation(Read more in our published study Lainas et al., 2005 Hum Reprod).
• A GnRH agonist can be administered to trigger ovulation, instead of the traditional hCG injection, completely avoiding the incidence of OHSS in high risk women.
• They are useful on Natural Cycles since premature follicular rupture and oocyte loss are avoided.
• They can be combined with the single injection protocol of corifollitropin –α (Elonva)